クロダ　ハジメ   Kuroda Hajime   黒田　一    所属   医学部 医学科（附属足立医療センター）    職種   教授
論文種別	症例報告
言語種別	英語
査読の有無	査読あり
表題	Primary diffuse large B-cell lymphoma of the breast.
掲載誌名	正式名：Breast cancer (Tokyo, Japan) 略　 称：Breast Cancer ISSNコード：13406868/13406868
掲載区分	国外
巻・号・頁	14(3),pp.317-22
著者・共著者	Kuroda Hajime†*, Tamaru Jun-ichi, Takeuchi Ikuya, Ohnisi Kiyoshi, Toyozumi Yasuo, Momose Shuji, Itoyama Shinji
担当区分	筆頭著者,責任著者
発行年月	2007
概要	Diffuse large B cell lymphoma (DLBL) of the breast is a rare subtype of breast tumor, the diagnosis of which is based on the cytological and histopathological features of this unique neoplasm. A 28-year-old woman noticed a mass in her right breast. It could not be definitely diagnosed clinically by diagnostic imaging (mammography, ultrasonography), so malignant tumor not otherwise specified was diagnosed. Fine-needle aspiration cytology (FNAC) suggested that it was malignant lymphoma; however it was difficult to distinguish from reactive lymphocytes. Excisional biopsy of the breast mass suggested malignant lymphoma. Based on the diagnosis of malignant lymphoma by FNAC and excisional biopsy, lumpectomy was performed and DLBL was diagnosed histologically according to the World Health Organization classification. DLBL is difficult to distinguish from other types of malignant lymphoma by routine immunohistochemical evaluation. Some previous studies have showed that the octamer-binding transcription factor 2 (Oct2) and coactivator B-cell Oct-binding protein 1 (BOB.1) and the pan-B-cell markers CD20 and CD79a may aid in the diagnosis of malignant lymphoma. In our case, the staining of large atypical lymphocytes for CD20, CD79a, BOB.1 and Oct2 was strongly positive and supports the notion that BOB.1 and Oct2 are also useful immunohistochemical markers for DLBL of the breast.
DOI	10.2325/jbcs.14.317
PMID	17690512